质子治疗与容积旋转调强放疗在高危复发乳腺癌综合再照射中臂丛神经保护的比较评估
该计划研究纳入10例既往接受锁骨上区和上腋窝光子放疗后同侧复发乳腺癌患者,比较笔束扫描质子治疗(PBS-PT)与光子容积旋转调强放疗(VMAT)对臂丛神经的保护。结果显示PBS-PT改善了臂丛神经保护和靶区覆盖,作者认为对于臂丛神经重叠且预期寿命较长的高危非转移性复发乳腺癌患者,质子治疗可能是首选治疗方式。
要点
- PBS-PT较VMAT改善了臂丛神经保护和靶区覆盖。
- 10例患者中2例高累积臂丛最大剂量者出现臂丛神经病症状。
- 作者认为对臂丛重叠且预期寿命较长的高危复发患者,质子治疗可能是首选。
核心结论
- PBS-PT较VMAT改善了臂丛神经保护和靶区覆盖。
- 对于需要综合再照射、臂丛神经重叠且预期寿命较长的高危非转移性复发乳腺癌患者,质子治疗可能是首选治疗方式。
研究设计与样本
- 经机构审查委员会批准的计划研究,纳入10例既往光子放疗后同侧复发乳腺癌并接受PBS-PT再照射且与既往光子放疗至少部分臂丛重叠的患者。
- 为每例患者制定匹配臂丛剂量约束的VMAT对比计划(XRT1)。
- 另创建一对使用标准化靶区的质子(PBT2)和VMAT(XRT2)计划,处方剂量50.4 Gy(每次1.8 Gy),臂丛最大约束<25 Gy。
- 同时评估臂丛神经病的发生率。
主要发现
- 两次放疗中位间隔48个月(范围15-276)。
- 首次、第二次和中位累积放疗剂量分别为50.4 Gy(范围42.6-60.0)、50.4 Gy(RBE)(范围45.0-64.4)和102.4 Gy(RBE)(范围95.0-120.0)。
- 中位随访15个月(范围5-33),存活患者为18个月(范围11-33)。
- PBT1的臂丛平均最大剂量为37.5 Gy(RBE),XRT1为36.9 Gy。
- XRT1的靶区覆盖率V85%、V90%和V95%在数值上低于PBT1;PBT2在V55%、V65%、V75%、V85%和V95%剂量水平上腋窝I-III区和锁骨上区覆盖率显著高于XRT2,仅腋窝I区V55%未达显著性(P=0.06),倾向于PBS-PT。
关键数值与推荐
- 标准化计划处方剂量为50.4 Gy(每次1.8 Gy),臂丛最大约束<25 Gy。
- 比较计划中臂丛剂量约束匹配。
临床怎么用
- 作者认为对于需要综合再照射、臂丛神经重叠且预期寿命较长的高危非转移性复发乳腺癌患者,质子治疗可能是首选治疗方式。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Recurrent or new primary breast cancer requiring comprehensive regional nodal irradiation after prior radiation therapy (RT) to the supraclavicular area and upper axilla is challenging due to cumulative brachial plexus (BP) dose tolerance. We assessed BP dose sparing achieved with pencil beam scanning proton therapy (PBS-PT) and photon volumetric modulated arc therapy (VMAT). METHODS AND MATERIALS: In an institutional review board-approved planning study, all patients with ipsilateral recurrent breast cancer treated with PBS-PT re-RT (PBT1) with at least partial BP overlap from prior photon RT were identified. Comparative VMAT plans (XRT1) using matched BP dose constraints were developed. A second pair of proton (PBT2) and VMAT (XRT2) plans using standardized target volumes were created, applying uniform prescription dose of 50.4 per 1.8 Gy and a maximum BP constraint <25 Gy. Incidence of brachial plexopathy was also assessed. RESULTS: Ten consecutive patients were identified. Median time between RT courses was 48 months (15-276). Median first, second, and cumulative RT doses were 50.4 Gy (range, 42.6-60.0), 50.4 Gy relative biologic effectiveness (RBE) (45.0-64.4), and 102.4 Gy (RBE) (95.0-120.0), respectively. Median follow-up was 15 months (5-33) and 18 months for living patients (11-33) Mean BP max was 37.5 Gy (RBE) for PBT1 and 36.9 Gy for XRT1. Target volume coverage of V85% (volume receiving 85% of prescription dose), V90%, and V95% were numerically lower for XRT1 versus PBT1. Similarly, axilla I-III and supraclavicular area coverage were significantly higher for PBT2 than XRT2 at dose levels of V55%, V65%, V75%, V85%, and V95%. Only axilla I V55% did not reach significance (P = .06) favoring PBS-PT. Two patients with high cumulative BPmax (95.2 Gy [RBE], 101.6 Gy [RBE]) developed brachial plexopathy symptoms with ulnar nerve distribution neuropathy without pain or weakness (1 of 2 had symptom resolution after 6 months without intervention). CONCLUSIONS: PBS-PT improved BP sparing and target volume coverage versus VMAT. For patients requiring comprehensive re-RT for high-risk, nonmetastatic breast cancer recurrence with BP overlap and reasonable expectation for prolonged life expectancy, PBT may be the preferred treatment modality.
引用
- Choi JI, McCormick B, Park P, et al. Comparative Evaluation of Proton Therapy and Volumetric Modulated Arc Therapy for Brachial Plexus Sparing in the Comprehensive Reirradiation of High-Risk Recurrent Breast Cancer. Adv Radiat Oncol. 2023. PMID: 38405315. doi:10.1016/j.adro.2023.101355
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。